Loading quotes...
Forecast
The analysts' average price target is €36.84 (-12.47%). The median is €38.71 (-8.03%).
| Buy |
Â
5 |
| Hold |
Â
1 |
| Sell |
Â
0 |
News Go to news feed
Heartflow climbs to new record high of $51.26
Heartflow stock reached an all-time high of $51.26 after strong gains in recent months (about +110% in 6 months, +73% year-to-date). In Q2 2026 the company reported adjusted earnings of -$0.07 per share and revenue up 48% to $64.1 million, with both metrics beating estimates. In response, Stifel raised its price target to $45.00 and reiterated a "Buy" rating, while some valuations consider the stock overvalued relative to fair value. » More on de.investing.com
Heartflow hits record high of $48.70 after strong Q2 results
Heartflow shares rose to a record high of $48.70, about 1% below the 52-week high; the stock is up 86% over the past six months. In Q2 2026 the company beat expectations with adjusted EPS of -$0.07 (estimate -$0.19) and revenue rising 48% to $64.1 million. Stifel raised its price target to $45.00 and affirmed its "Buy" rating, while InvestingPro notes the stock may be overvalued at current levels. » More on de.investing.com
HeartFlow beats Q2 expectations, raises full-year guidance and stock jumps after hours
HeartFlow reported an adjusted loss per share of $0.07 for Q2 2026, beating consensus by $0.12. Revenue rose 48% to $64.1 million and gross margin climbed to 83.3%, driven by strong plaque business and AI-powered automation. The company raised its full-year guidance to $246–250 million in revenue and a non-GAAP gross margin of about 82%; the stock rose roughly 16–17% after hours. While HeartFlow remains unprofitable, it expects to be cash-flow positive by mid-2028 and is showing accelerated revenue and margin growth. » More on de.investing.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 56.15M | 52.41% |
| Gross profit | 46.61M | 67.59% |
| Net profit | -13.79M | 76.80% |
| EBITDA | -13.77M | 4,276.26% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.63B |
Number of shares | 86.24M |
52-week high/low | €44.54 - €17.32 |
| Dividends | No |
Beta | 2.02 |
P/E ratio | -34.44 |
PEG ratio | 4.77 |
P/B ratio | 15.11 |
P/S ratio | 19.89 |
Company profile
HeartFlow, Inc. ist ein Medizintechnikunternehmen, das weltweit nicht-invasive Lösungen für die Diagnose und Behandlung von Koronararterienerkrankungen anbietet. Seine HeartFlow-Plattform nutzt KI und numerische Strömungsmechanismen, um aus einer einzigen Koronar-Computertomographie-Angiographie, einer speziellen Art von Scan, der detaillierte Bilder der Herzarterien liefert, ein personalisiertes 3D-Modell des Herzens eines Patienten zu erstellen. Die Plattform des Unternehmens bietet Einblicke in den Blutfluss, die Verengung sowie das Volumen und die Zusammensetzung von Plaque, indem sie die Einschränkungen herkömmlicher nicht-invasiver Bildgebungstests überwindet. Das Unternehmen wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in Mountain View, Kalifornien.
| Name | HeartFlow |
| CEO | John Farquhar |
| Website | |
| IPO | 08/07/2025 |
| Employees | 843 |
Deep Dive
Discover assets
Shareholders of HeartFlow also invest in the following assets